Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Asciminib · Scemblix, ABL-001

Small molecule · Inhibitor of BCR-ABL1 fusion protein (ABL1 kinase) (ABL1) · developed by Novartis

Approved FDA, Oct 2021
NVS Developer
2 Registered trials

What is Asciminib?

Asciminib is an orally bioavailable, allosteric BCR-ABL1 tyrosine kinase inhibitor that binds the myristoyl pocket of the BCR::ABL1 fusion protein, distinct from the ATP-binding site, and inhibits wild-type and mutant forms including T315I. It is being studied in Philadelphia chromosome-positive leukemias, including chronic myelogenous leukemia and acute lymphoblastic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Scemblix, ABL-001, ABL001-NX
Drug type
Small molecule
Targets
BCR-ABL1 fusion protein (ABL1 kinase) (ABL1)
Mechanism
Inhibitor of BCR-ABL1 fusion protein (ABL1 kinase) (ABL1)
Pathways
BCR-ABL1 tyrosine kinase signaling, leukemic cell proliferation, apoptosis
Therapy area
Oncology
Developer
Novartis (NVS)
FDA status
Approved as Scemblix (October 29, 2021), NDA215358 · FDA label
UNII
L1F3R18W77

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 25, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07387926 Phase 1/2 Acute Lymphoblastic Leukemia Recruiting NVS
NCT07936266 Phase 1 B-cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-PositivePhiladelphia Chromosome-Positive

Other drugs acting on ABL1

More from Novartis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Asciminib

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.